Anteris Technologies Global Corp. (AVR)
Anteris Technologies Global Corp. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Eagan, MN, US. The stock last traded at $8.78, down 4.25% on the session, giving a market capitalisation of $853.7M. On trailing twelve-month figures it carries a trailing P/E of -2.57, a net margin of -4619.7%. Its beta of 0.73 implies it has historically moved less than the broad market.
Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.
Anteris Technologies Global Corp. is most often compared with the following Healthcare names: